Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Makes New Adult Immunization Push, Seeks Reimbursement Changes Following RSV Approvals

Executive Summary

From ACIP to Part D to data transparency, GSK has several policy asks as it prepares to launch its new RSV vaccine for older adults. The Pink Sheet spoke with GSK’s vaccine policy lead about the firm’s new data platform and the worrisome US vaccination trends following the Covid pandemic.

You may also be interested in...



AstraZeneca’s RSV Antibody May Need More Data Due To Impact Of Maternal Vaccines

Maternal vaccines may cause first RSV infections to occur when infants are older, requiring increased study of disease patterns and additional dosing data on AstraZeneca/Sanofi’s nirsevimab in older babies. 

Pfizer, GSK US RSV Vaccine Uptake Likely Hurt By ACIP’s Weaker Recommendation

Price tag, inadequate trial designs, safety and questions about possibility of boosters were among the reasons CDC advisors voted that adults 60 and over ‘may’ receive an RSV vaccine. A stronger ‘should’ receive RSV vaccine had seemed possible for the over 65 group earlier this year.

GSK’s Walmsley On US v. EU COVID-Flu Combos, RSV Branding, And Investing In Infectious Disease

COVID vaccine makers already licensed in the US will have a leg up on in the combination respiratory vaccine space since aspiring new entrants like GSK will have to do efficacy work to get FDA approval. CEO Walmsley offers insight into the company’s vaccine strategy.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel